Wockhardt tanks amid concerns over long-drawn resolution of FDA warning
This article was originally published in Scrip
Executive Summary
Shares of Wockhardt have nosedived on Indian bourses amid investor concern that resolving good manufacturing practice (GMP) issues at the company's Waluj site in Aurangabad may be a long-drawn out affair and that this could hurt the firm's performance significantly in the short-term.